CellCept 1 g/5 ml powder for oral suspension
Sponsors
Eledon Pharmaceuticals Inc., Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen, F. Hoffmann-La Roche AG
Conditions
COVID-19Childhood Idiopathic Nephrotic SyndromeHerpes ZosterLupus Nephritis (LN)Prophylaxis of Renal Allograft Rejectionimpaired immunitykidney transplantation
Phase 2
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Active, not recruitingCTIS2023-503336-41-00
Start: 2023-11-29Target: 101Updated: 2025-07-22
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 To < 12)
RecruitingCTIS2023-505825-15-00
Start: 2021-10-29Target: 10Updated: 2025-05-03
Phase 3
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
CompletedCTIS2023-503894-39-00
Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10
A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome
RecruitingCTIS2023-505140-19-00
Start: 2023-07-31Target: 26Updated: 2025-03-21